NCT04096768

Brief Summary

The aim of the study is to compare the use of dexmedetomidine + ketamine with dexmedetomidine + placebo for sedation in ICU patients in terms of safety and efficacy

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
394

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Sep 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 15, 2019

Completed
1 day until next milestone

Study Start

First participant enrolled

September 16, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 20, 2019

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 16, 2021

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

February 20, 2020

Status Verified

February 1, 2020

Enrollment Period

2 years

First QC Date

September 15, 2019

Last Update Submit

February 18, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Measuring blood pressure to assess hypotension when using a combination of the two drugs for sedation versus Dexmedetomidine and placebo only

    Measuring blood pressure to assess hypotension when using a combination of the two drugs for sedation versus Dexmedetomidine and placebo only

    Within 24 hours of drugs administration

Secondary Outcomes (1)

  • Measuring the doses of dexmedetomidine and ketamine when combined and the doses of dexmedetomidine when used alone to achieve desired level of sedation

    Within 24 hours of drugs administration

Study Arms (2)

Dexmedetomidine + Ketamine

EXPERIMENTAL
Drug: DexmedetomidineDrug: Ketamine

Dexmedetomidine + Placebo

PLACEBO COMPARATOR
Drug: Dexmedetomidine

Interventions

Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients

Dexmedetomidine + KetamineDexmedetomidine + Placebo

Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients

Dexmedetomidine + Ketamine

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age between 18-80 years old
  • Admitted to Intensive care unit at LAUMCRH
  • Need for sedation for at least 24 hours
  • Informed Consent Form signed by patient or surrogate

You may not qualify if:

  • Pregnant patients
  • At risk of increased intracranial pressure
  • Aortic dissection
  • Acute coronary syndrome
  • Hypertension (SBP \> 180 mmHg)
  • Chronic alcoholism
  • Acute alcohol intoxication
  • Alcohol withdrawal
  • Refractory status epilepticus
  • History of psychiatric disorder
  • Known allergy or contraindication to use of dexmedetomidine or ketamine
  • Baseline hypotension (MAP\<65 mmHg)
  • Baseline bradycardia (HR\<48 bpm)
  • Patients receiving neuromuscular blocking agents
  • Patients requiring deep sedation as determined by the ICU attending

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Lebanese American University Medical Center- Rizk Hospital

Beirut, 00000, Lebanon

RECRUITING

MeSH Terms

Interventions

DexmedetomidineKetamine

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Central Study Contacts

Fayez Abillama, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Intensive Care Medicine Physician

Study Record Dates

First Submitted

September 15, 2019

First Posted

September 20, 2019

Study Start

September 16, 2019

Primary Completion

September 16, 2021

Study Completion

December 30, 2021

Last Updated

February 20, 2020

Record last verified: 2020-02

Locations